[Clinical study of ambulatory patient cancer chemotherapy for advanced colorectal cancer].

Szczegóły
Abstrakt

Tytuł:: [Clinical study of ambulatory patient cancer chemotherapy for advanced colorectal cancer].
Autorzy:: Toyokawa A; Dept. of Surgery, Yodogawa Christian Hospital.
Tsujimura T
Hamabe Y
Sato S
Mukubou H
Wakahara T
Kaji M
Tsukamoto T
Wakita K
Onishi N
Ishida T
Watanabe A
Fujiwara H
Mukai H
Źródło:: Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2005 Dec; Vol. 32 (13), pp. 2087-90.
Typ publikacji:: English Abstract; Journal Article
Język:: Japanese
Imprint Name(s):: Publication: Tokyo : Gan To Kagaku Ryohosha
Original Publication: Tōkyō, Gan to Kagaku Ryōhōsha [1974?]-
MeSH Terms:: Ambulatory Care*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Colorectal Neoplasms/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Administration, Oral ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Colorectal Neoplasms/mortality ; Drug Administration Schedule ; Drug Combinations ; Female ; Humans ; Leucovorin/administration & dosage ; Male ; Middle Aged ; Nausea/chemically induced ; Stomatitis/chemically induced ; Survival Rate ; Tegafur/administration & dosage ; Uracil/administration & dosage
Substance Nomenclature:: 0 (Drug Combinations)
0 (UFT(R) drug)
1548R74NSZ (Tegafur)
56HH86ZVCT (Uracil)
Q573I9DVLP (Leucovorin)
Entry Date(s):: Date Created: 20051215 Date Completed: 20060106 Latest Revision: 20131121
Update Code:: 20240104
PMID:: 16352933
: Czasopismo naukowe

To evaluate ambulatory patient cancer chemotherapy, the clinical response, toxicities and survival time were analysed among 19 patients with non-curative or recurrent colorectal cancer who were treated by Uracil/Tegafur (UFT) plus oral Leucovorin (UZEL) for the past 2 years. The patients were administered UFT (300 mg/m2/day) and UZEL (75 mg/body/day) for 28 days with a one-week interval every 35 days as one course.A partial response (PR) was observed in 6 patients (31.6%) and stable disease (SD) in 8. The median survival time was 16 months. Although nausea/vomiting, diarrhea and leucopenia were noted, no severe side effects were observed. These results suggested that UFT plus Leucovorin therapy might be a useful cancer chemotherapy for ambulatory patients with advanced colorectal cancer.

Informacja